Immunoglobulins enable patients with serious and rare diseases to lead normal lives. In order to meet the great global demand, the biotechnology company CSL Behring massively expanded its production capacities in Bern. The expansion project designated ‘Protinus’ allows an additional 90,000 patients per year to lead normal lives.
The two ultra-modern production units lie at the core of the CHF 300 million investment project. They produce 16 tonnes of immunoglobulins every year. The two process plants were put into operation in October 2020.
amotec prefabricated tanks, platforms and pipelines in its own workshop. After factory acceptance, several assembly teams made a major effort to transport the plant components from Münsingen (or from the assembly hall) to Bern-Wankdorf and install them in the new Protinus building.